A5083199261- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Mobile Health and mHealth Applications
- Gastroesophageal reflux and treatments
- Chronic Kidney Disease and Diabetes
- Pharmaceutical Economics and Policy
- Metabolism, Diabetes, and Cancer
- Gastrointestinal motility and disorders
- Lipoproteins and Cardiovascular Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Medication Adherence and Compliance
- PARP inhibition in cancer therapy
- Systemic Lupus Erythematosus Research
- Healthcare Systems and Public Health
- Advanced Breast Cancer Therapies
- Patient-Provider Communication in Healthcare
- Liver Diseases and Immunity
- Cardiovascular Health and Risk Factors
- BRCA gene mutations in cancer
- Chronic Disease Management Strategies
- Blood Pressure and Hypertension Studies
- Health disparities and outcomes
- Heart Failure Treatment and Management
- Diabetes Management and Research
- Dialysis and Renal Disease Management
AstraZeneca (United States)
2015-2024
AstraZeneca (United Kingdom)
2022
Massachusetts General Hospital
2022
Welch Foundation
2018
Johns Hopkins University
2018
Johns Hopkins Medicine
2018
African Americans have persistently poor access to living donor kidney transplants (LDKT). We conducted a small randomized trial provide preliminary evidence of the effect informational decision support and financial assistance interventions on American hemodialysis patients' pursuit LDKT.Study participants were randomly assigned receive (1) Usual Care; (2) Providing Resources Enhance Patients' Readiness Make Decisions about Kidney Disease (PREPARED); or (3) PREPARED plus program. Our...
Objective: Estimate the economic burden associated with incremental increases in number of cardiometabolic risk factors (CMRFs) US. Methods: We used nationally representative Medical Expenditure Panel Survey from 2010 to 2012 create a retrospective cohort people based on CMRFs (one, two, and three or four), comparison zero CMRFs. included abdominal obesity, elevated blood pressure, triglycerides, glucose were defined using diagnostic codes, prescribed medications, survey responses. Adjusted...
This retrospective study of community oncology patients with breast cancer gene (BRCA)-mutated metastatic (MBC) examined treatment outcomes and health resource utilization (HRU) costs for a sample human epidermal growth factor receptor 2 (HER2)-negative disease who were either hormone positive (HR+) or triple negative (TNBC). Evidence from the Vector Oncology Data Warehouse, repository electronic medical records/billing data provider notes, was analyzed. Treatment progression-free survival...
The DAPA-CKD trial assessed dapagliflozin in patients with chronic kidney disease (CKD) or without type 2 diabetes (T2D). To aid interpretation of results, renal and cardiovascular outcomes plus healthcare resource utilization (HCRU) costs were a real-world population similar to that DAPA-CKD. Henry Ford Health System (2006–2016) data used identify CKD stages 2–4 [estimated glomerular filtration rate (eGFR) 25–75 ml/min/1.73 m2 at index urine albumin-to-creatinine ratio (UACR) 0–5000 mg/g; n...
<h3>Background:</h3> Renal disease is a common severe manifestation of systemic lupus erythematosus (SLE), occurring in 50%-60% patients [1]. function SLE changes dynamically over time, with periods declining glomerular filtration rate also among without nephritis [2]. Treatment may stabilize renal from trajectory. Anifrolumab was approved the US 2021 for use adults moderate to SLE; however, limited robust real-world data currently available on outcomes following anifrolumab treatment...
Prescribing patterns and suboptimal adherence present methodological challenges for real-world head-to-head comparisons of ticagrelor clopidogrel in intent-to-treat studies. The aim this study was to compare an on-treatment population. This retrospective cohort used the Optum™ Clinformatics™ database identify patients with acute coronary syndrome (ACS) discharged on or between January 1, 2012 September 30, 2019. primary end point hospitalization myocardial infarction (MI); secondary major...
Introduction: To characterize changes in statin utilization patterns after the release of 2013 ACC/AHA cholesterol management guideline. Methods: Using administrative claims and laboratory results data from HealthCore Integrated Research Database, use was captured during 4 quarters before Individuals were classified into benefit groups (SBG), as described Patients new to statins identified independently each quarter. Results: An average 205,358 patients across SBG quarter, whom an 3,658...
Background: Severe hypertriglyceridemia is an often-neglected risk factor that associated with increased of cardiovascular disease, pancreatitis and mortality, especially when other comorbidities are present. We investigated the association between triglyceride (TG)-lowering therapy subsequent reduction in TG levels patients diabetes very high triglycerides (VHTG). Methods: combined data from Southern California Northwest regions Kaiser Permanente to identify a measurement > 500 mg/dL...
Background: Optimal heart failure (HF) management after hospitalization requires ongoing care coordination. Digital approaches with a unified disease platform (DMP) experience may improve patient care. Objective: A single-arm single-institution pilot study to assess feasibility of implementation and engagement DMP among HF patients for 60 days post-hospitalization. Methods: The included clinician electronic medical record-integrated dashboard patient-facing smartphone app that provided...
Abstract Background and Aims Recent studies have shown an association between Sodium Glucose Co-Transporter 2 inhibitor (SGLT-2i) class of drugs lower healthcare costs compared with other glucose lowering therapy, in type diabetes (T2D) patients mainly as a result reduced rates cardiovascular T2D-associated outcomes. The DAPA-CKD Trial (A study to evaluate the effect dapagliflozin on renal outcomes CV mortality CKD) is first SGLT-2i trial test efficacy safety SGLT-2i, dapagliflozin, CKD...
Abstract Background and Aims The Sodium Glucose Co-Transporter 2 inhibitor (SGLT-2i) class of drugs have demonstrated significant cardiorenal benefits in patients with type diabetes (T2D), including reducing the composite renal outcome eGFR decline, End Stage Kidney Disease (ESKD) or death T2D preserved function also overt Diabetic Disease. In addition, SGLT-2i proven to beneficial effects on cardiovascular (CV) outcomes heart failure reduced ejection fraction (HFrEF) independent glycaemic...
Background: Current guidelines recommend ticagrelor over clopidogrel as part of DAPT regimen for ACS treatment. However, real-world head-to-head assessment and has been methodologically challenging due to prescribing patterns adherence. Thus, we conducted an on-treatment comparative analysis utilizing a large national payer data within US. Methods: A retrospective cohort study patients discharged on or between January 1, 2012 September 30, 2019 was the Optum TM Clinformatics data. Patients...